Vivienne Kahlmann, a PhD candidate at Erasmus MC and a pulmonologist specializing in interstitial lung diseases at Leiden University Medical Center.

Lower baseline forced vital capacity (FVC) and shorter disease duration were associated with a stronger treatment response to first-line prednisone or methotrexate in patients with 

, according to a post-hoc analysis of the PREDMETH trial presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain.¹

The randomized PREDMETH trial, published in the 

 in 2025, found methotrexate noninferior to prednisone as first-line treatment for pulmonary sarcoidosis, with mean FVC gains of 6.11 and 6.75 percentage points at week 24, respectively (adjusted difference, −1.17 percentage points; 95% CI, −4.27 to 1.93).² A recent Delphi consensus of international sarcoidosis experts endorsed an improvement of 10% predicted or more in FVC as a clinical trial endpoint.³ Whether study inclusion criteria influence the likelihood of reaching this threshold had not been established.¹

"Patients with a lower FVC were likely to respond better than patients with a higher FVC," said Vivienne Kahlmann, a PhD candidate at Erasmus MC and a pulmonologist specializing in interstitial lung diseases at Leiden University Medical Center, in an interview with HCPLive. "This has implications for future trial design. When we design trials, we may use baseline FVC, for example, as a stratification factor to divide patients equally across both groups."

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response

Baseline FVC and Treatment Response in the PREDMETH Trial

PREDMETH randomized 138 patients with treatment-naive pulmonary sarcoidosis at centers across the Netherlands to receive prednisone (n = 70) or methotrexate (n = 68).² In the post-hoc analysis, Kahlmann and colleagues evaluated predictors of FVC change at week 24 using univariate and multivariate linear regression, with data available for 135 patients.¹ Responder analyses stratified patients by baseline FVC at the median of 77% predicted and defined response as improvements of ≥ 5% and ≥ 10%.¹

In univariate analysis, baseline FVC, age, and disease duration were each associated with FVC change at week 24.¹ Treatment assignment to prednisone or methotrexate showed no association with FVC change.¹ In the multivariate model, greater baseline FVC % predicted (

 <.001) and longer disease duration in years (

 =.022) were both associated with smaller FVC improvement, and age did not reach significance (

Patients with baseline FVC < 77% predicted were more likely to reach the 5% response threshold (odds ratio [OR], 2.80; 

 =.004) and the 10% threshold (OR, 2.34; 

 =.021) compared with patients at or above the median.¹ Kahlmann noted many Delphi panelists also supported a 5% threshold, with consensus ultimately forming around 10%.

"[When] looking at endpoints in clinical trials, it's better not to look binary at whether patients reach the 10% threshold or not, but more at continuous data," said Kahlmann. Her team is now examining optimal FVC cutoff points alongside secondary measures, including diffusing capacity and patient-reported outcomes.

Disease Duration, Biomarkers, and Future Sarcoidosis Trial Design

Lower baseline FVC and shorter disease duration were associated with greater FVC improvement at 24 weeks in a post-hoc PREDMETH analysis.

Patients with baseline FVC below 77% predicted had greater odds of 5% (OR, 2.80) and 10% (OR, 2.34) FVC improvement.

Investigators suggest baseline FVC stratification for future trials; blood biomarker and CT phenotype studies are underway.

Kahlmann described the disease duration signal as modest. She said the association was small and is not yet relevant for clinical decision-making. Identifying patients most likely to respond to a given therapy remains the broader goal of ongoing work in the Dutch cohort.

Colleagues are evaluating blood biomarkers as potential predictors of response, Kahlmann said. For methotrexate, the team is measuring blood drug levels to assess any link with treatment response. For prednisone, investigators are studying glucocorticoid receptor expression, hypothesizing patients with greater receptor expression respond better to corticosteroid therapy.

Kahlmann recently received a grant from the Foundation for Sarcoidosis Research to investigate whether baseline CT imaging phenotypes predict treatment response. The work builds on a prior Delphi consensus defining 7 radiological phenotypes of sarcoidosis, and her team is assessing whether response differs across these phenotypes. She identified biomarkers as a major unmet need in sarcoidosis, with research underway internationally.

“There is a lot of research going on [about] biomarkers in sarcoidosis because I think that's also a major unmet need yet, and hopefully we will define in the future better biomarkers,” Kahlmann said.

Kahlmann V, Bogaard V, Moor C, et al. Baseline forced vital capacity and disease duration associate with treatment response in pulmonary sarcoidosis. Presented at European Respiratory Society Congress 2026; September 5-9, 2026; Barcelona, Spain.

Kahlmann V, Janssen Bonás M, Moor CC, et al. First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate. 

Baughman RP, Grutters JC, Lower EE, et al. Pulmonary sarcoidosis clinical trial end-points: a Delphi study. 

Videos

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

David Kendall, MD | Image Credit: LinkedIn

ZUPREME-2, a phase 2 trial of investigational long-acting human amylin analog petrelintide, has achieved its primary endpoint of superior reductions in body weight among patients with overweight or 

Announced by parent company Zealand Pharma on October 7, 2026, these results are consistent with the prior ZUPREME-1 trial, which established the drug’s efficacy in patients with overweight or obesity without T2D. The full data from ZUPREME-2 are expected to be presented at an upcoming medical conference.

“These results further support the potential of petrelintide in chronic weight management and, for the first time, demonstrate its promise as a standalone treatment for those living with overweight or obesity and type 2 diabetes,” David Kendall, MD, chief medical officer at Zealand Pharma, said in a statement. “These data confirm the potential for clinically meaningful weight reduction with a promising and favorable tolerability profile.”

ZUPREME-2 was a randomized, double-blind, phase 2 trial of petrelintide once weekly in patients with overweight or obesity and T2D. Patients were eligible for inclusion if they had been diagnosed with T2D ≥180 days before screening, had a body mass index (BMI) ≥27 kg/m2, and were receiving treatment with metformin with or without SGLT2 inhibitors. Patients were excluded if they had severe hypoglycemia within 6 months before screening, a self-reported change in body weight >5% within 90 days, or obesity due to endocrine disorder or genetic syndromes, among other criteria.

The trial included a screening period, a dose escalation period of ≤16 weeks with escalation taking place every fourth week, and a maintenance period until week 28. This was followed by a follow-up period until week 38. The primary endpoint for the study was percentage change in body weight from baseline to week 28. Secondary outcomes included the number of patients achieving ≥5% and ≥10% body weight loss by week 28, change in body weight in kg, change in waist circumference, HbA1c, fasting glucose, and hsCRP, among others.

A total of 220 patients were enrolled in the trial, with a mean baseline BMI of 36.3 kg/m2 and a mean baseline HbA1c of 8%. These patients were then randomized to receive 3 separate doses of either petrelintide or placebo, all of which were administered once weekly and subcutaneously. By week 28, investigators reported that patients receiving petrelintide achieved ≤9.2% mean weight loss from baseline, while the placebo arm saw ≤2% mean weight loss. Additionally, petrelintide demonstrated a substantial reduction in HbA1c across all treatment arms, with a placebo-adjusted HbA1c reduction of 0.61-0.88%.

The investigators also recorded no unexpected safety signals during the trial. Petrelintide demonstrated a favorable tolerability profile, and treatment discontinuation rates due to gastrointestinal adverse events were 1.9% for the petrelintide arm and 1.7% for the placebo arm. Additionally, the majority of adverse events were gastrointestinal, and the vast majority of these were reportedly mild and occurred during the escalation period.

Zealand Pharma and petrelintide co-developer Roche have already initiated a Phase 3a program for petrelintide, consisting of the ZUPREME-3, ZUPREME-4, and ZUPREME-5 trials. This program plans to evaluate patients with overweight or obesity without T2D, with T2D, and established cardiovascular disease, respectively. Zealand Pharma plans to enroll roughly 7000 patients across all 3 trials.

“Together with Roche, we look forward to investigating petrelintide in our recently initiated Phase 3 registrational program to address important unmet medical needs in chronic weight management,” Kendall said in a statement.

Zealand Pharma. Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes. 

. October 7, 2026. Accessed October 7, 2026. 

https://www.globenewswire.com/news-release/2026/10/07/3376750/0/en/zealand-pharma-announces-positive-phase-2-zupreme-2-topline-results-for-amylin-analog-petrelintide-in-people-with-overweight-or-obesity-and-type-2-diabetes.html

Zealand Pharma. Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2). ClinicalTrials.gov Identifier: NCT06926842. Updated September 9, 2026. Accessed October 7, 2026. 

https://clinicaltrials.gov/study/NCT06926842?term=NCT06926842&rank=1

Articles

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

Jacquelyn M. Powers, MD, MS, is section chief of hematology at Texas Children's Hospital and associate professor in the department of pediatrics at Baylor College of Medicine. She chaired the ASH panel that wrote the iron deficiency diagnosis guidelines.

She is an expert in the management of iron deficiency anemia, with expertise in both oral iron supplementation and the indications for and use of intravenous iron therapy. Her research aims to better identify patients at risk for iron deficiency and find the most successful treatment approach for children and adolescents with iron deficiency anemia. She is particularly interested in patient-centered outcomes such as fatigue and quality of life in children treated with oral or intravenous iron. 

She also served as a lead author of a revised American Academy of Pediatrics (AAP) clinical report, published in the July 2026 issue of Pediatrics, which was the first major update to pediatric iron deficiency guidance in nearly a decade

Jacquelyn Powers, MD, MS.png

Commonly used ferritin cutoffs miss many patients who are iron deficient and could benefit from treatment, according to the chair of the 

 panel behind the society's first guideline on diagnosing iron deficiency. To set new cutoffs, the panel compared thresholds population by population.

"The serum ferritin threshold of 15 was specifically chosen because that is the recommendation used by the World Health Organization, and then 30 was used because a lot of evidence suggests that 30 might be a more appropriate physiologic threshold," said Jacquelyn M. Powers, MD, MS, guideline chair, section chief of 

 at Texas Children's Hospital, and associate professor of pediatrics at Baylor College of Medicine, in an interview with 

. "And then there is some data to suggest that certain patients feel better if you target a higher ferritin threshold of 50 or more, and that individuals continue to absorb iron up until their ferritin is 50."

Why ASH's New Guidelines Raise Ferritin Thresholds, With Jacquelyn Powers, MD, MS

 includes 5 recommendations developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. It recommends a serum ferritin threshold of ≤30 ng/mL for most adults, including menstruating and pregnant individuals, and ≤20 ng/mL for children aged 9 months to 4 years. These thresholds apply whether or not 

Why ASH Prioritized Iron Deficiency Diagnosis Before Treatment

ASH Clinical Practice Guidelines in Development and Remaining Evidence Gaps in IDA Management

Diagnosing Iron Deficiency Anemia — Ferritin Thresholds, Confirmatory Testing, and Workup

3 Hematology Headlines You Missed in September 2026

Each year, ASH asks its members to propose blood conditions that have new evidence but no existing guideline. Several years ago, members proposed guidance on diagnosing and treating iron deficiency, and ASH chose to prioritize it.

Iron deficiency affects patients from infancy to older adulthood, and many types of clinicians manage it. Powers noted that not all of those clinicians know the full range of signs and symptoms. She added that many commonly used lab values and thresholds miss a large number of patients who are iron deficient.

Because accurate identification has to come before treatment, the panel focused first on diagnosis, and specifically on serum ferritin. It is the most commonly used test for iron deficiency and serves as a marker of the body's iron stores. ASH expects to release treatment guidance in 2027.²

Comparing Ferritin Thresholds of 15, 30, and 50 ng/mL Across Populations

For adults who are not menstruating or pregnant, pregnant individuals, and menstruating adolescents and adults, the panel compared ferritin thresholds of 15, 30, and 50 ng/mL. These are the thresholds where most of the evidence on diagnostic accuracy, treatment response, and symptoms is concentrated.

The panel evaluated each threshold separately for each group. The prevalence of iron deficiency and the needs of patients differ across populations, so a new cutoff could have a different effect in each group. For adults with inflammation, the guideline recommends a ferritin <100 ng/mL or a transferrin saturation <20%.¹

Why Young Children Need a Separate Ferritin Threshold

"That's not because children have less iron needs necessarily, but because they're going through a rapid period of growth," Powers said. "They're really using that iron much more actively compared to adult populations, and so it's just kind of a different phase of life physiologically, how they're using that iron."

For young children, the panel compared ferritin thresholds of 12 ng/mL, the World Health Organization cutoff, and 20 ng/mL. Powers explained that some data suggest children continue to absorb iron until ferritin reaches about 20 ng/mL, after which absorption may plateau. The guideline recommends ≤20 ng/mL for this age group.¹

Editor's Note: Powers reported no relevant disclosures.

Powers JM, Lim MY, Achebe MO, et al. American Society of Hematology 2026 guidelines for diagnosis of iron deficiency. 

 2026. doi:10.1182/bloodadvances.2025015950

American Society of Hematology. ASH sets new standards for diagnosing iron deficiency. Medical Xpress. September 16, 2026. 

https://medicalxpress.com/news/2026-09-ash-standards-iron-deficiency.html

The guideline chair explains the evidence behind the 15, 30, and 50 ng/mL ferritin cutoffs and a separate pediatric threshold.

Hematology

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido) for adults with 

 (SD), the most common form of chronic inducible urticaria, inadequately controlled by H1 antihistamines, based on data from the phase 3 RemIND trial.

announced the approval expanding the therapy’s indication beyond chronic spontaneous urticaria (CSU) on October 7.

The decision makes remibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, the first therapy approved specifically for SD and the only agent indicated for both SD and CSU, according to Novartis.

 The FDA first approved remibrutinib for CSU in 2025 on the strength of the phase 3 REMIX-1 and REMIX-2 trials.

 The SD indication uses the same 25 mg twice-daily oral dose.

“SD is a chronic, debilitating condition with historically limited treatment options,” said Giselle Mosnaim, MD, MS, allergist and immunologist, Endeavor Health, and lead RemIND investigator. “Remibrutinib offers, for the first time, an approach to treatment specifically for SD patients who remain inadequately controlled with H1 antihistamines alone, representing a meaningful step forward for this population.”

Remibrutinib is approved for adults with chronic spontaneous urticaria or symptomatic dermographism who remain symptomatic despite H1 antihistamine treatment. The recommended dose is 25 mg orally twice daily.

Remibrutinib is an oral, selective BTK inhibitor. It blocks Fc epsilon receptor 1 signaling in mast cells and basophils, inhibiting degranulation and release of histamine and other proinflammatory mediators.

In RemIND, 29.3% of patients receiving remibrutinib achieved a complete Total Fric Score response at week 12 vs 14.0% with placebo, with separation from placebo evident by week 2.

What was Remibrutinib’s efficacy in the phase 3 RemIND trial?

RemIND was a 52-week, multicenter, randomized, double-blind, placebo-controlled trial (NCT05976243) enrolling 115 adults with SD for at least 4 months despite background H1 antihistamines.

 Eligibility required a Total Fric Score (TFS) of 3 or higher (range, 0–4) on FricTest 4.0 and an itch numerical rating scale (NRS) score of 5 or higher after provocation.

 Patients were randomized 1:1 to remibrutinib 25 mg or placebo twice daily for 24 weeks, followed by a 28-week open-label period on remibrutinib.

Mean patient age was 39.2 years, 71.3% (82/115) of patients were female, and 58.3% (67/115) had a baseline TFS of 4.

 Mean disease duration at enrollment was 5.8 years.

At week 12, 29.3% (17/58) of patients receiving remibrutinib achieved a complete TFS response (TFS = 0), compared with 14.0% (8/57) receiving placebo (treatment difference, 15.0%; 95% CI, 0.3–29.7; 

 Improvements in TFS and itch NRS at week 12 were consistent regardless of baseline total IgE level, according to the label.

Secondary endpoints and safety of remibrutinib in SD

At week 2, the earliest secondary timepoint, 29.3% of remibrutinib-treated patients achieved a complete TFS response vs 8.8% with placebo (treatment difference, 20.5%; 95% CI, 6.6–34.4).

 At week 24, complete response rates were 32.8% vs 15.8% (treatment difference, 15.6%; 95% CI, 0.3–30.9).

Remibrutinib reduced itch NRS by a least squares (LS) mean of 4.0 points from baseline at week 2, compared with 1.8 points for placebo (LS mean difference, −2.2; 95% CI, −3.2 to −1.2).

 All primary and secondary endpoints reached statistical significance.

Through week 24, safety in the SD population (remibrutinib, n = 58; placebo, n = 57) was consistent with safety in CSU, per the prescribing information.

 In the pooled CSU trials, the most common adverse reactions were nasopharyngitis (11%), bleeding (9%), headache (7%), nausea (3%), and abdominal pain (3%), with no severe bleeding events.

 Novartis noted no routine laboratory monitoring is required.

The label advises interrupting remibrutinib for 3 to 7 days before and after surgery and avoiding live or live-attenuated vaccines.

 Concomitant strong or moderate CYP3A4 inhibitors and inducers should be avoided, as should use in patients with mild, moderate, or severe hepatic impairment.

RemIND also evaluated remibrutinib in cold urticaria and cholinergic urticaria, and Novartis plans to submit the full dataset to health authorities globally.

 The company is studying remibrutinib in hidradenitis suppurativa and food allergy and recently reported positive phase 3 REMODEL-1 and REMODEL-2 results vs teriflunomide in relapsing multiple sclerosis.

Novartis. Novartis Rhapsido (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU). Published October 7, 2026. Accessed October 7, 2026. 

https://www.novartis.com/us-en/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu

Rhapsido. Prescribing information. Novartis Pharmaceuticals Corp; 2026. Accessed October 7, 2026. 

https://www.novartis.com/us-en/sites/novartis_us/files/rhapsido.pdf

HCPLive. Trial data and safety of remibrutinib for CSU. 

https://www.hcplive.com/view/trial-data-and-safety-of-remibrutinib-for-csu

. Published July 15, 2026. Accessed October 7, 2026.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

W. Timothy Garvey, MD | Image Credit: UAB

CBL-514 has successfully reduced visceral adipose tissue (VAT) in patients with 

 or overweight, according to new readouts from the CBL-0204 and CBL-0205 studies.

In development by Caliway Biopharmaceuticals, CBL-514 is a first-in-class small-molecule injection that specifically and selectively induces adipocyte apoptosis. In both preclinical models and the aforementioned Phase 2 trials, CBL-514, administered either independently or in combination with GLP-1 medications, has demonstrated substantial synergistic reductions in L2-L3 VAT.

“We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss,” W. Timothy Garvey, MD, professor of medicine in the department of nutrition sciences at the University of Alabama at Birmingham, said in a statement. “But it is the reduction in body weight, loss of visceral fat, and the improvements in blood pressure, cholesterol, and the like that should be associated with this that will be important for health.”

Garvey and colleagues conducted an analysis including patients from the CBL-0204 and CBL-0205 with a body mass index (BMI) of 22-30 kg/m2 and a body weight change of <6.61 lb. Patients with evaluable MRI data were included in the L2-L3 VAT assessment. The team quantified VAT volume from MRI scans via AI-assisted segmentation with predefined anatomical boundaries.

A total of 46 patients were ultimately included in the analysis. Among the 26 patients receiving CBL-514, baseline VAT volume was 642.5 mL compared to 677.4 mL in the 20-patient placebo group. Garvey and colleagues evaluated changes from baseline at week 4 and weeks 8-12, analyzing absolute and percentage shifts.

By week 4, mean VAT volume had dropped by 65.5 mL in the CBL-514 arm and increased by 29.4 mL in the placebo arm. The team calculated a treatment difference of -94.9 mL by t-test (

 = .0015). A Hodges-Lehmann median difference estimate returned -73.4 mL (

 = .0009). Percentage change from baseline was -10.9% in the CBL-514 arm compared to 4.6% with placebo, which corresponded to a treatment difference of -15.5% by t-test (

At week 8-12, mean VAT volume decreased by 58.1 mL in the treatment arm and risen by 79.4 mL in the placebo arm, resulting in a treatment difference of -137.5 mL by t-test (

 = .0015), while the Hodges-Lehmann estimated difference was -116 mL (

 = .0020). Percentage change was -7.3% among patients receiving treatment and 18.4% among those assigned to placebo. Treatment difference was -25.7% by t-test (

Garvey and colleagues conducted parametric and non-parametric analyses, confirming that these findings were consistent and supporting CBL-514’s efficacy in this indication. These results are also consistent with previous animal studies, further establishing the drug’s potential metabolic benefits in isolation and with GLP-1 receptor agonists.

“This is a highly innovative approach to obesity pharmacotherapy that has produced some remarkable results in early human trials,” Garvey said in a statement.

European Association for the Study of Diabetes. New weight-loss injection targets fat cells – CBL-514 is designed to reduce levels of subcutaneous and visceral fat. 

. October 1, 2026. Accessed October 7, 2026. 

https://www.eurekalert.org/news-releases/1146063

Ling Y, Liang M, Garvey T, et al. CBL-514, a first-in-class adipocyte apoptosis-inducing injection, reduces MRI-measured L2-L3 visceral adipose tissue: translational evidence from preclinical models to a Phase 2 clinical trial. Abstract presented at the European Association for the Study of Diabetes (EASD), Milan, Italy. September 28-October 2, 2026.

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

Brian Lee, MD, is a hepatologist and liver transplant specialist with Keck School of Medicine of USC.

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

Hepatology

Why Alcohol-Associated Liver Disease May Not Have Peaked, With Brian Lee, MD

Florence Schleich, MD, PhD, a respiratory physician at the University of Liège in Belgium.

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

10 Nephrology Headlines You Missed in Q3 2026

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q3 2026 Recap: Dermatology News & Updates

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD, discusses LATITUDE Atlas data showing zasocitinib achieved higher PASI 100 rates than deucravacitinib in psoriasis.

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Edward Chen, MD, is a professor of surgery at Thomas Jefferson University and the chief of cardiac surgery at Jefferson Abington Hospital.

Chen discusses his experience with aortic and cardiac surgery, as well as ongoing research into ways to optimize and improve care.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Structural Heart Disease

Strategic Alliance Partnership

Updates and Evolution in Aortic Disease Care, With Edward Chen, MD

Hisamitsu Hayashi, PhD, in the Graduate School of Pharmaceutical Sciences associate professors at the University of Tokyo.

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.

RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

Latest News

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

Why ASH's New Guidelines Raise Ferritin Thresholds, With Jacquelyn Powers, MD, MS

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity